Peer-influenced content. Sources you trust. No registration required. This is HCN.
Specialty Pharmacy Continuum
Across the board, for all outcomes—acute pancreatitis, all-cause mortality, hospitalizations, ICU admissions—we saw significant reductions in patients on GLP-1s compared to chronic pancreatitis patients not on these drugs.” – Mahmoud Y. Madi, MD
Ambulatory Care Pharmacy (BCACP) October 14th 2025
US Pharmacist
Pharmacists are instrumental in recognizing MOH, counseling patients who rely on analgesics more than twice weekly, and encouraging preventive therapies.
Internal Medicine October 14th 2025
Pharmacy Times
This updated indication now allows the use of upadacitinib prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least 1 approved systemic therapy.
Clinical Pharmacology October 14th 2025